

DAFTAR PUSTAKA

- Bartalena, L., Kahaly, G. J., Baldeschi, L., et al. (2021). *The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy*. *European Journal of Endocrinology*, 185(1), G43–G67.
- Bartalena, L., Gallo, D., Tanda, M. L., & Kahaly, G. J. (2023). *Thyroid eye disease: Epidemiology, natural history, and risk factors*. *Ophthalmic Plastic & Reconstructive Surgery*, 39(6S), S2–S8.
- Cardo, C., Santos, R. B., Miklos, A. B. P. P., Jaconis, S. B., Romaldini, J. H., & Villagelin, D. (2025). *The relationship between cholesterol levels and thyroid eye disease*. *European Thyroid Journal*, 14(1).
- Caroline, Y. Y., Ford, R. L., Wester, S. T., & Shriver, E. M. (2022). *Update on thyroid eye disease: Regional variations in prevalence, diagnosis, and management*. *Indian Journal of Ophthalmology*, 70(7), 2335–2345.
- Chng, C. L., Lai, O. F., Chew, C. S. M., Peh, Y. P., Fook-Chong, S. M. C., Seah, L. L., & Khoo, D. H. C. (2014). *Hypoxia increases adipogenesis and affects adipocytokine production in orbital fibroblasts: A possible explanation of the link between smoking and Graves' ophthalmopathy*. *International Journal of Ophthalmology*, 7(3), 403.
- Chin, Y. H., Ng, C. H., Lee, M. H., Koh, J. W. H., Kiew, J., Yang, S. P., et al. (2020). *Prevalence of thyroid eye disease in Graves' disease: A meta-analysis and systematic review*. *Clinical Endocrinology*, 93(4), 363–374.
- Diana, T., Brown, R. S., Bossowski, A., Segni, M., Niedziela, M., König, J., et al. (2014). *Clinical relevance of thyroid-stimulating autoantibodies in pediatric Graves' disease: A multicenter study*. *Journal of Clinical Endocrinology & Metabolism*, 99(5), 1648–1655.
- Douglas, R. S., Kahaly, G. J., Patel, A., et al. (2020). *Teprotumumab for the treatment of active thyroid eye disease*. *New England Journal of Medicine*, 382(4), 341–352.
- Eckstein, A. K., Loesch, C., Glowacka, D., Schott, M., Mann, K., Esser, J., & Morgenthaler, N. G. (2009). *Euthyroid and primarily hypothyroid patients develop milder and*

significantly more asymmetrical Graves ophthalmopathy. British Journal of Ophthalmology, 93(8), 1052–1056.

Greco, D., Pisciotta, M., Gambina, F., & Maggio, F. (2011). *Graves' disease in subjects with type 1 diabetes mellitus: A prevalence study in western Sicily (Italy)*. Primary Care Diabetes, 5(4), 241–244.

Heisel, C. J., Riddering, A. L., Andrews, C. A., & Kahana, A. (2020). *Serum vitamin D deficiency is an independent risk factor for thyroid eye disease*. Ophthalmic Plastic & Reconstructive Surgery, 36(1), 17–20.

Johnson, B. T., Jameyfield, E., & Aakalu, V. K. (2021). Optic neuropathy and diplopia from thyroid eye disease: update on pathophysiology and treatment. *Current opinion in neurology*, 34(1), 116-121.

Kementerian Kesehatan Republik Indonesia. (2010). *Peraturan Menteri Kesehatan Republik Indonesia Nomor 340/Menkes/Per/III/2010 tentang Klasifikasi Rumah Sakit*. Kementerian Kesehatan RI.

Klingenstein, A., Samel, C., Garip-Kübler, A., Hintschich, C., & Müller-Lisse, U. G. (2022). *Cross-sectional computed tomography assessment of exophthalmos in comparison to clinical measurement via Hertel exophthalmometry*. Scientific Reports, 12, 11973.

Kulbay, M., Tanya, S. M., Tuli, N., Dahoud, J., Dahoud, A., Alsaleh, F., et al. (2024). *A comprehensive review of thyroid eye disease pathogenesis: From immune dysregulations to novel diagnostic and therapeutic approaches*. International Journal of Molecular Sciences, 25(21), 11628.

Kumari, R., & Chandra Saha, B. (2018). *Advances in the management of thyroid eye diseases: An overview*. International Ophthalmology, 38, 2247–2255.

Kurniawan, A. R., Sutjipto, & Atika. (2022). *Karakteristik dan distribusi pasien trauma okuli di instalasi rawat darurat RSUD Dr. Soetomo Surabaya pada tahun 2014*. Jurnal Kesehatan Soetomo, 9(2), 53–58.



- Lanzolla, G., Sabini, E., Profilo, M. A., Mazzi, B., Sframeli, A., Rocchi, R., et al. (2018). *Relationship between serum cholesterol and Graves' orbitopathy (GO): A confirmatory study*. Journal of Endocrinological Investigation, 41(12), 1417–1423.
- Lanzolla, G., Vannucchi, G., Ionni, I., Campi, I., Sileo, F., Lazzaroni, E., & Marinò, M. (2020). *Cholesterol serum levels and use of statins in Graves' orbitopathy: A new starting point for the therapy*. Frontiers in Endocrinology, 10, 1–8.
- Lesko, C. R., Fox, M. P., & Edwards, J. K. (2022). *A framework for descriptive epidemiology*. American Journal of Epidemiology, 191(12), 2063–2070.
- Lim, N. C., Sundar, G., Amrith, S., & Lee, K. O. (2015). *Thyroid eye disease: A Southeast Asian experience*. British Journal of Ophthalmology, 99(4), 512–518.
- Limantoro, C., & Arimadyo, A. K. (2019). *Hubungan faktor risiko terhadap kejadian ophthalmopathy Graves*. Jurnal Kedokteran Diponegoro, 8(4), 1248–1256.
- Lutfiyah, Z. S., Lutfi, D., Susanto, H., & Sutjipto. (2024). *Correlation of TED laterality with thyroid status among thyroid eye disease (TED) patients in a tertiary hospital in Indonesia*. Current Internal Medicine Research and Practice Surabaya Journal, 5(1). <https://doi.org/10.20473/cimrj.v5i1.51726>
- Mourits, M. P. H., Koornneef, L., Wiersinga, W. M., Prummel, M. F., Berghout, A., & Van Der Gaag, R. (1989). *Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: A novel approach*. British Journal of Ophthalmology, 73(8), 639–644.
- Müller-Forell, W., & Kahaly, G. J. (2012). *Neuroimaging of Graves' orbitopathy*. Best Practice & Research Clinical Endocrinology & Metabolism, 26(3), 259–271.
- Mulya, F. D., & Eran, F. K. (2021). *Analisis faktor risiko kejadian ophthalmopathy Graves di RSUP Dr. Mohammad Hoesin Palembang periode 2018–2021*.
- Muñoz-Ortiz, J., Sierra-Cote, M. C., Zapata-Bravo, E., Valenzuela-Vallejo, L., Marin-Noriega, M. A., Uribe-Reina, P., et al. (2020). *Prevalence of hyperthyroidism, hypothyroidism, and euthyroidism in thyroid eye disease: A systematic review*. Systematic Reviews, 9, 201.



- Eckstein, A. (2024). How Age Affects Graves' Orbitopathy—A Tertiary Center Study. *Journal of Clinical Medicine*, 13(1), 290.
- Park, K., Li, J., Wen, J., Li, S., Lee, J., Danesh, K., et al. (2024). *Extraocular muscle enlargement in thyroid eye disease using volumetric analysis*. *Cureus*, 16(7), e63843.
- Park, N. R., Moon, J. H., & Lee, J. K. (2019). *Hertel exophthalmometer versus computed tomography scan in proptosis estimation in thyroid-associated orbitopathy*. *Clinical Ophthalmology*, 13, 1461–1467.
- Perros, P., Bartalena, L., Kahaly, G. J., et al. (2016). *The European Group on Graves' Orbitopathy (EUGOGO) guidelines for the management of Graves' orbitopathy*. *European Journal of Endocrinology*, 174(3), G1–G30.
- Prummel, M. F., Wiersinga, W. M., Mounts, M. P., Koornneef, L., Berghout, A., & van der Gaag, R. (1990). *Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy*. *Archives of Internal Medicine*, 150(5), 1098–1101.
- Rachmasari, K. N., Thapa, P., Sighoko, D., Abdul Jabbar, L., & Stan, M. N. (2023). *The epidemiology of thyroid eye disease in Olmsted County, Minnesota*. *Journal of the Endocrine Society*, 7(Supplement 1).
- Ramamurthy, L. B., Rangarajan, V., Srirao, N., Malini, B., Bansal, R., & Yuvarajan, K. (2020). *Severity of thyroid eye disease and type-2 diabetes mellitus: Is there a correlation?* *Indian Journal of Ophthalmology*, 68(6), 1127–1131.
- Sadeghi-Tari, A., Jamshidian-Tehrani, M., Nabavi, A., Sharif-Kashani, S., Elhami, E., Hassanpour, N., & Ameli Zamani, K. (2016). *Effect of smoking on retrobulbar blood flow in thyroid eye disease*. *Eye*, 30(12), 1573–1578.
- Ross, D. S., Burch, H. B., Cooper, D. S., Greenlee, M. C., Laurberg, P., Maia, A. L., et al. (2016). *2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis*. *Thyroid*, 26(10), 1343–1421.
- Shah, S. S., & Patel, B. C. (2022). *Thyroid eye disease*. StatPearls Publishing.



Sabini, E., Mazzi, B., Profilo, M. A., Mautone, T., Casini, G., Rocchi, R., et al. (2018). *High serum cholesterol is a novel risk factor for Graves' orbitopathy: Results of a cross-sectional study*. *Thyroid*, 28(3), 386–394.

Selter, J. H., Gire, A. I., & Sikder, S. (2014). The relationship between Graves' ophthalmopathy and dry eye syndrome. *Clinical Ophthalmology*, 57-62.

Shah, S., Stokkermans, T., & Patel, B. (2025). *Thyroid eye disease*. StatPearls.

Stan, M. N., & Bahn, R. S. (2010). *Risk factors for development or deterioration of Graves' ophthalmopathy*. *Thyroid*, 20(7), 777–783.

Szelog, J., Swanson, H., Sniegowski, M. C., & Lyon, D. B. (2022). *Thyroid eye disease*. *Missouri Medicine*, 119(4), 343.

Tsai, C. C., Kau, H. C., Kao, S. C., & Hsu, W. M. (2006). *Exophthalmos of patients with Graves' disease in Chinese of Taiwan*. *Eye*, 20(5), 569–573.

Ulla, M. U., Nivean, P., Abrar, M., & Madhivanan, N. (2024). *Clinical profile of thyroid eye disease and factors predictive of disease severity in Chennai District of Tamil Nadu*. *TNOA Journal of Ophthalmic Science and Research*, 62(3), 325–330.

Watanabe, E. M., Cavazzana, R. Y., Ribeiro, D. D. A. M., Brandão, L. C., Haddad, A. V., Corrente, J. E., et al. (2024). *Morphometric analysis of extraocular muscles and proptosis by computed tomography in Graves' orbitopathy*. *Radiologia Brasileira*, 57, e20240040.

Wiersinga, W. M., Eckstein, A. K., & Žarković, M. (2025). *Thyroid eye disease (Graves' orbitopathy): Clinical presentation, epidemiology, pathogenesis, and management*. *The Lancet Diabetes & Endocrinology*.

Yang, M., & He, W. (2024). *Age and gender influence on clinical manifestations of thyroid-associated ophthalmopathy: A case series of 2479 Chinese patients*. *Frontiers in Endocrinology*, 15, 1434155.

Zloto, O., Sagiv, O., Priel, A., Cukierman-Yaffe, T., Tirosh, A., Agmon-Levin, N., et al. (2021). *Gender differences in clinical presentation and prognosis of thyroid eye disease*. *European Journal of Ophthalmology*, 31(5), 2717–2723.